

September 19, 2008  
Mitsubishi Chemical Holdings Corporation

**Mitsubishi Tanabe Pharma Corporation will Conclude  
the Basic Agreement with the National Plaintiffs Group on the HCV Class Action**

Mitsubishi Chemical Holdings Corporation (Head office: Minato-ku, Tokyo; President: Yoshimitsu Kobayashi) announces that its subsidiary, Mitsubishi Tanabe Pharma Corporation will conclude the basic agreement with the national plaintiffs group on the HCV class action. As for details, please refer to the attached press release.

For further information, please contact:

Public Relations and Investor Relations Office  
Mitsubishi Chemical Holdings Corporation  
TEL: +81-(0)3-6414-4870

September 19, 2008  
Mitsubishi Tanabe Pharma Corporation

**The Basic Agreement to Be Concluded with the National Plaintiffs Group  
on the HCV Class Action**

Mitsubishi Tanabe Pharma Corporation (“the Company”) announced that its Board of Directors resolved that the Basic Agreement is to be concluded with the national plaintiffs group and its lawyers in order to solve the cases, as the Company and its subsidiary Benesis Corporation (“Benesis”) were sued for compensatory damages by those who claimed to have been infected with HCV (hepatitis C virus) via administration of the fibrinogen preparation and the blood coagulation factor IX preparation Christmassin made and sold by one of its predecessor companies Green Cross Corporation. The Basic Agreement is scheduled to be concluded on September 28.

These cases currently examined in the regional and higher courts will be terminated after conclusion of the Basic Agreement, as the plaintiffs groups will sequentially disclaim compensation from Benesis and the Company.

While the government proclaimed and enforced “the Special Relief Law Concerning the Payment of Benefits to Relieve the Patients of Hepatitis C Infected through Specified Fibrinogen Preparations and Specified Blood-Coagulation Factor IX Preparations Contaminated by Hepatitis C Virus” on January 16, 2008, we will discuss and determine the measures and ratios of benefit payments with the Minister of Health, Labour and Welfare, according to the terms of the Article 16 in this special measures law (discussion between the Minister of Health, Labour and Welfare and manufacturers, etc).

As announced on May 7, 2008, the Company posted for future loss for these cases by budgeting 11.2 billion yen as “reserve for HCV litigations” in the business year ended in March 2008. However, the amount of our payment may change depending on future discussions and increase/decrease in number of those who should receive the benefits.